Personalis (NASDAQ:PSNL) Hits New 1-Year High - Here's Why

Key Points

• Personalis shares hit a new 52-week high of $17.04 and were recently trading at $16.46, up 5.6% from the prior close. The company’s market capitalization reached approximately $1.75 billion.
• Analyst sentiment remains mixed, with four Buy, three Hold and two Sell ratings, resulting in a consensus Hold rating and an average price target of $14.25—below the current share price.
• In its latest quarter, Personalis reported revenue of $22.36 million, exceeding estimates, but missed EPS expectations with a loss of $0.30 per share. Insiders have also sold 435,032 shares worth about $5.6 million over the past 90 days.

Personalis, Inc. (NASDAQ:PSNL - Get Free Report)'s share price reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $17.04 and last traded at $16.4580, with a volume of 2215499 shares trading hands. The stock had previously closed at $15.81.

Analyst Ratings Changes

PSNL has been the topic of a number of recent research reports. Lake Street Capital lowered shares of Personalis from a "buy" rating to a "hold" rating and set a $16.25 price objective on the stock. in a research note on Monday, July 20th. Needham & Company LLC lowered shares of Personalis from a "buy" rating to a "hold" rating in a report on Monday, July 20th. TD Cowen restated a "buy" rating on shares of Personalis in a research note on Wednesday, July 15th. Morgan Stanley boosted their price objective on Personalis from $9.00 to $13.00 and gave the company an "equal weight" rating in a research report on Thursday, July 9th. Finally, Wall Street Zen cut Personalis from a "hold" rating to a "sell" rating in a research note on Saturday, June 13th. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, Personalis currently has a consensus rating of "Hold" and an average target price of $14.25.

Personalis Trading Up 5.6%

The stock has a fifty day moving average price of $12.97 and a 200 day moving average price of $9.57. The firm has a market cap of $1.75 billion, a price-to-earnings ratio of -15.31 and a beta of 2.27.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.04). Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. The firm had revenue of $22.36 million during the quarter, compared to analyst estimates of $16.69 million. On average, sell-side analysts forecast that Personalis, Inc. will post -1.07 EPS for the current year.

Insider Activity at Personalis

In other news, CEO Christopher M. Hall sold 100,000 shares of the stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $13.15, for a total transaction of $1,315,000.00. Following the completion of the transaction, the chief executive officer directly owned 235,986 shares in the company, valued at $3,103,215.90. This represents a 29.76% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 51,251 shares of the stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $13.18, for a total transaction of $675,488.18. Following the completion of the transaction, the chief financial officer directly owned 198,833 shares in the company, valued at $2,620,618.94. The trade was a 20.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 435,032 shares of company stock valued at $5,599,929 over the last ninety days. Company insiders own 4.20% of the company's stock.

Institutional Investors Weigh In On Personalis

Several large investors have recently added to or reduced their stakes in PSNL. Jasper Ridge Partners L.P. purchased a new stake in Personalis during the 2nd quarter valued at $193,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Personalis by 7,822.5% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 87,068 shares of the company's stock valued at $1,167,000 after buying an additional 85,969 shares during the last quarter. Bank of America Corp DE purchased a new position in shares of Personalis in the 2nd quarter worth $24,395,000. Jupiter Topco LLC purchased a new stake in shares of Personalis in the second quarter worth approximately $405,000. Finally, ADAR1 Capital Management LLC purchased a new position in Personalis during the 2nd quarter worth $201,000. Institutional investors own 61.91% of the company's stock.

Personalis Company Profile

Personalis, Inc NASDAQ: PSNL is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company's core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source